Disclosed herein are pharmaceutical compositions comprising [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid ([18F]FACBC, commonly known as [18F]-Fluciclovine), and a 50-100 mM citrate buffer and having a pH between 4 and 5 which provides for decreased radiolysis, and not more than 150 µg/mL 1-amino-3-hydroxyl-cyclobutane-1-carboxylic acid (hydroxyl-ACBC). Also disclosed is a method to obtain said pharmaceutical composition.